Overview of Dicloberl

Property	Description
Active Ingredient	Diclofenac (as sodium or potassium salt)
Form	Tablets, prolonged-release capsules, solution for injection, suppositories, topical gel
Pharmacological Class	Non-steroidal anti-inflammatory drug (NSAID)
General Use	Symptomatic relief of pain, inflammation, and fever
Origin	Synthetic compound

Dicloberl: Classification and Active Ingredient

Dicloberl is a well-recognized European prescription-only medicine whose single active ingredient is Diclofenac, a synthetic compound used primarily to combat pain and inflammation. This drug is definitively classified as a Non-steroidal anti-inflammatory drug (NSAID). This classification confirms that the medicine works to reduce pain, inflammation, and fever throughout the body, a mechanism that is clinically recognized across pharmacological studies. Diclofenac is further categorized as a Phenylacetic acid derivative, distinguishing its chemical structure from other common NSAIDs like naproxen or ibuprofen. As a potent systemic treatment, Diclofenac is engineered to intervene broadly in the body’s inflammatory cascade.

Forms and Differentiation

The core substance, Diclofenac, is available across a variety of pharmaceutical preparations to ensure flexibility in delivery, which is a key distinguishing feature of the Dicloberl line. These preparations include standard oral tablets, specialized prolonged-release hard capsules (such as Dicloberl Retard) designed for sustained action, a sterile solution for injection intended for intramuscular administration, and topical gel for application to the skin. Diclofenac products are utilized for their analgesic and anti-inflammatory properties. This diverse range of forms, which also includes suppositories, allows the drug to be introduced via the oral route, rectal route, or directly into muscle tissue, confirming the product is a monotherapy containing a single active pharmacological component.

How Dicloberl Provides General Relief

Dicloberl provides general relief by leveraging the potent physiological action of its active ingredient to reduce the internal factors driving discomfort. This substance works by acting as a highly effective inhibitor of the Cyclooxygenase (COX) enzyme, which is responsible for creating prostaglandins. Prostaglandins are the chemical messengers that signal pain, increase local swelling, and elevate body temperature. The general purpose of the medication is therefore to deliver rapid symptomatic treatment that simultaneously mitigates pain, suppresses inflammation, and provides an antipyretic effect (fever reduction).

Regulatory References

NIH, National Library of Medicine

What side effects are possible with Dicloberl?

Possible Side Effects and Safety Information

The safety profile of Dicloberl is documented by regulatory authorities and includes adverse reactions classified by frequency and affected body systems.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on how often they have been reported in clinical data and post-marketing surveillance:

Common (may affect up to 1 in 10 people): Headache, dizziness, gastrointestinal symptoms (including nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, flatulence, anorexia), and elevated liver enzymes.
Rare (may affect up to 1 in 1,000 people): Hypersensitivity reactions (including anaphylactic and anaphylactoid reactions), asthma, gastrointestinal bleeding, ulceration, hepatitis, or jaundice.
Very Rare (may affect up to 1 in 10,000 people): Severe bullous skin reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), bone marrow depression, and serious cardiovascular events.

Serious and Systemic Safety Concerns

Regulatory documents emphasize the risk of serious arterial thrombotic events, such as myocardial infarction (heart attack) and stroke, particularly when the medicine is used at high doses or for long periods. The risk of these events is considered to be dose- and duration-dependent.

Another major safety concern is the potential for severe gastrointestinal adverse events, including bleeding, ulceration, or perforation, which can occur without prior warning symptoms and may be fatal.

Adverse reactions affecting the liver (hepatobiliary disorders, including liver failure) and kidneys (renal and urinary disorders, including acute renal failure) are also key components of the documented safety profile.

Safety-Related Restrictions

The medicine is contraindicated and must not be used in patients with established congestive heart failure (NYHA class II–IV), ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease. It is also contraindicated in patients with an active or history of recurrent peptic ulcer or gastrointestinal haemorrhage and during the third trimester of pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation requires individuals who suspect an overdose of Dicloberl (Diclofenac) to seek immediate medical attention or contact emergency services and poison control centers right away. This urgency is mandated because an overdose, even when initially appearing mild, can rapidly progress to severe, life-threatening outcomes.

Documented Overdose Manifestations and Severe Outcomes:

Classification	Official Regulatory Statements
Common Manifestations	Nausea, vomiting, epigastric pain, headache, dizziness, and tinnitus (ringing in the ears).
Severe Outcomes	Gastrointestinal hemorrhage, acute renal or hepatic failure, convulsions (seizures), coma, and hypotension (low blood pressure).

Mandated Emergency Actions and Management

The regulatory profile emphasizes that no specific antidote is known for acute Diclofenac toxicity. Treatment is strictly defined as symptomatic and supportive. In the hospital setting, measures may include the administration of activated charcoal for recent, large ingestions, and close medical supervision. Monitoring is required, focusing on vital signs and laboratory parameters such as renal and hepatic function, with an extended observation period necessary for sustained-release formulations. Elderly patients and those with pre-existing organ impairment are officially noted to be at an increased risk for serious adverse events following an overdose.

Therapeutic Uses of Dicloberl

Dicloberl: Main Uses and Benefits

Dicloberl is used to help manage pain and inflammation associated with various medical conditions. Its primary therapeutic purpose is to provide relief from the signs and symptoms of several types of arthritis, including osteoarthritis and rheumatoid arthritis.

The medication also provides benefit for managing the discomfort and symptoms of ankylosing spondylitis, a form of arthritis that primarily affects the spine.

Additional uses for this drug include managing acute pain and easing symptoms related to painful menstrual periods (primary dysmenorrhea). Furthermore, certain formulations may be used for the acute treatment of migraine headache attacks in adults. This medication is not intended to prevent migraines or reduce the number of future attacks.

Consult a healthcare professional to understand the appropriate use for your specific condition. Comprehensive details on the approved therapeutic domains are available in the official prescribing information.

Quick Facts (Therapeutic Focus)

Relief of signs and symptoms associated with osteoarthritis and rheumatoid arthritis.
Used to manage symptoms of ankylosing spondylitis.
Provides management of acute pain in adults.
May offer benefit for primary dysmenorrhea (painful menstrual periods).
Used for acute treatment of migraine headaches.

Eligibility and Restrictions for Use

Official Dicloberl Eligibility and Restrictions

Dicloberl (diclofenac) eligibility is defined by official regulatory documentation concerning pre-existing conditions, allergic history, and life stage. Use of systemic formulations is restricted to adults and certain adolescents (12 years and older).

Contraindicated Populations (Must Not Use):

Classification	Exclusion Criteria (Official Labeling)
Cardiovascular/Surgical	Established Ischaemic Heart Disease, Peripheral Arterial Disease, Cerebrovascular Disease, Congestive Heart Failure (NYHA Class II-IV), or status following Coronary Artery Bypass Graft (CABG) surgery.
Hypersensitivity	Known allergy to diclofenac or a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.

Restricted or Conditional Use:

Pregnancy (Third Trimester): Use is strictly avoided from 30 weeks gestation onward. Use is limited between 20 and 30 weeks.
Organ Function: Avoid use in patients with advanced renal disease or severe heart failure. Use requires caution in hepatic impairment.
Age: Elderly patients are at greater risk for serious gastrointestinal and renal adverse events and require special caution. Use in children under 12 years is not established for many systemic forms.

What should I know about interactions with other medicines?

Dicloberl Interactions with Other Medicines and Products

Diclofenac's interaction profile is officially defined by its potential for pharmacokinetic alteration and pharmacodynamic reinforcement of adverse events, as documented in regulatory information.

Classification	Severity & Context
Contraindicated Combinations	Co-administration with other systemic NSAIDs, including COX-2 inhibitors and analgesic doses of Aspirin, is restricted due to additive risk of serious gastrointestinal events. It is also contraindicated for perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Clinically Significant Interactions	Anticoagulants and Anti-platelet agents carry a heightened risk of serious bleeding events upon co-administration. Interactions with Diuretics, ACE Inhibitors, and ARBs may diminish their effects and increase the risk of renal function deterioration.

Official Interaction Statements:

Exposure Modification: Diclofenac may increase the plasma concentration of certain co-administered medicines, including Lithium, Digoxin, and Methotrexate, by reducing their clearance.
Metabolic Pathway: The potent CYP2C9 inhibitor Voriconazole is documented to significantly increase Diclofenac plasma exposure.
Substance Restrictions: Consumption of alcohol is officially linked to an increased risk of gastrointestinal bleeding.
Timing Requirement: The oral solution formulation has an administration constraint, as taking it with food is documented to reduce its effectiveness.

Population-Specific Notes: The risk of renal function deterioration with co-administered blood pressure or fluid-management medicines (Diuretics, ACEI/ARBs) is higher in high-risk patients, including the elderly and those with pre-existing renal or hepatic impairment, according to prescribing information.

Mechanism of Action

Molecular Targeting of Cyclooxygenase Enzymes

The core action of Diclofenac is the inhibition of the Cyclooxygenase (COX) enzymes, specifically demonstrating preferential potency toward the COX-2 isoform. This interaction occurs at the enzyme's active site, competitively blocking the conversion of arachidonic acid into prostaglandins. This suppression of the eicosanoid pathway initiates subsequent physiological consequences.

Modulation of Inflammatory and Nociceptive Pathways

The reduced prostaglandin synthesis affects two primary physiological systems. Peripherally, decreased prostaglandin levels reduce the sensitization of nociceptive nerve endings, thereby altering the local signaling threshold. Systemically, the diminished availability of these mediators limits local vasodilation and vascular permeability, resulting in decreased local fluid accumulation (oedema).

️ Central Thermal Regulation

Diclofenac is also associated with action within the hypothalamus, where PGE2 synthesis is suppressed. This modulation directly affects the signaling that controls the central thermal set-point, leading to an adjustment of the body's thermoregulatory threshold.

Dosage and Administration Information

How to Use Dicloberl: Official Administration Guidelines

Dicloberl (Diclofenac) must be used strictly according to medical instructions to ensure proper administration. The overarching principle for all use is the administration of the lowest effective dose for the shortest duration possible.

Administration Scope and Dosing

Administration Aspect	Official Instruction
Approved Routes	Oral (tablets, capsules, powder), Rectal (suppositories), Intramuscular (IM) injection, Intravenous (IV) infusion, and Topical (gel).
Standard Oral Dose	Adult regimens typically range from 100 mg to 200 mg total daily dose, divided. The maximum recommended dose varies by indication but is often restricted to 150 mg or 200 mg per day.
Injectable Dose	75 mg once daily, or up to twice daily with doses separated by at least six hours, not to exceed 150 mg/24 hours.

Specific Use Requirements and Constraints

Oral Intake Conditions:

Prolonged-release forms (Retard) must be swallowed whole with liquid; they must not be crushed, split, or chewed to maintain the integrity of the controlled release.
The oral powder is instructed to be mixed with water and consumed on an empty stomach for rapid action.

Injectable Use:

IM Injection must be a deep intragluteal injection. The IV solution must be diluted and buffered prior to administration as an infusion; it is not for IV bolus (direct push).
The injectable route is restricted to a maximum of two consecutive days; treatment should transition to oral or rectal administration thereafter.

Population Rules:

Older adults should initiate treatment at the lowest possible effective dose. Dicloberl is not generally recommended for use in pediatric patients under 14 years of age.

Recent Clinical Evidence

Research evidence / Overview of Studies for Dicloberl

Evidence for Symptomatic Management of Chronic Arthritis

The evidence base for Diclofenac in the context of conditions such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis includes Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies were used in research exploring how symptoms change over time in conditions characterized by fluctuating manifestations. Researchers examined outcomes related to physical discomfort, outcomes linked to inflammatory or irritative states, and outcomes reflecting daily functioning or activity level across adult populations with established diagnoses.

Studies report how symptoms evolved in the observed populations, highlighting findings describe patterns observed in the studies regarding measured changes in pain intensity, joint stiffness measurements, and overall patient assessments. However, there is limited information for long-term outcomes and how functional measures evolve over periods beyond one year of treatment. The existing long-term data for systemic formulations, including studies conducted in settings with varying symptom burdens, were reviewed to assess evidence related to the duration of use.

Research Supporting Acute Pain and Rapid Symptom Control

Diclofenac was studied for use in conditions associated with acute or disruptive episodes, including research examining its application for general acute pain, primary dysmenorrhea, and the acute treatment of migraine attacks. This research primarily relies on short-term clinical trials focusing on episodes where symptoms become more noticeable.

Studies conducted during periods of increased symptom activity studies monitored the time until measured changes in outcomes describing episodic or acute changes were observed, and the duration of the observation period. The findings describe patterns observed in the studies across different arms, including those where the substance was evaluated in comparison to other agents. Follow-up durations were limited to the acute episode itself, meaning data for prolonged or repeated use in these specific contexts remain insufficient.

The Landscape of Evidence Gaps and Remaining Uncertainties

While a substantial body of research exists, certain uncertainties and gaps remain in the evidence landscape. Comparative evidence is lacking for certain formulations or indications when contrasted directly against every available therapeutic option. Evidence quality varies across studies, particularly when examining highly specific patient subgroups or rare manifestations of the studied conditions. Certainty remains low regarding the long-term effects are not fully established related to outcomes reflecting daily functioning or activity level.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dicloberl (FAQ)

Q: How quickly does Dicloberl start working?

The time required for the medicine’s active ingredient, diclofenac, to be absorbed and reach peak concentration is observed to vary based on the specific type of product used. For some immediate-release oral forms, the absorption process may be delayed by up to 4.5 hours if the medicine is taken with food.

Q: Does Dicloberl need to be taken with food?

Instructions for taking Dicloberl depend on the specific formulation. For instance, the oral powder form is often described in regulatory documents as being administered on an empty stomach to help ensure rapid action. While taking a delayed-release tablet with food may delay the medicine's onset, it may not significantly affect the total amount of the medicine absorbed.

Q: Can I take Dicloberl if I also take Tylenol (acetaminophen)?

Official drug information generally does not cite a direct interaction between diclofenac and acetaminophen. However, regulatory warnings stress that diclofenac should not be used in combination with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) due to an increased potential for adverse reactions.

Q: Are there any warnings about using Dicloberl with alcohol?

Yes, official regulatory information links the consumption of alcohol with an increased risk of gastrointestinal bleeding when the medicine is used. Official safety documents indicate that this documented risk should be considered.

Q: Can Dicloberl affect sleep or cause insomnia?

While insomnia is not consistently listed as a common side effect in regulatory documents, other central nervous system effects are documented. Official safety information does list dizziness and headache as common adverse reactions, and these effects may be experienced.

Q: How long does the pain relief from one dose of Dicloberl usually last?

The half-life of diclofenac, which is the time it takes for half the medicine to be cleared from the body, is approximately 1 to 2 hours. The duration of the therapeutic effect is observed to vary, and this is not a fixed value documented in regulatory documents.

Q: Is it okay to crush or break Dicloberl tablets?

No. Official administration instructions emphasize that prolonged-release forms (like Dicloberl Retard) must be swallowed whole with liquid. Crushing, splitting, or chewing these tablets is described as inappropriate, as it destroys the mechanism that controls the gradual release of the medicine.

Q: Can Dicloberl be taken by people with asthma?

Dicloberl is generally contraindicated in individuals with a history of asthma or allergic-type reactions (like hives) after previously taking aspirin or other NSAIDs. For people with pre-existing asthma who do not have an NSAID sensitivity, caution is still advised, according to official safety documents.

Q: Is Dicloberl the same as regular diclofenac?

Dicloberl is simply a brand name for a medicine whose active ingredient is diclofenac. Generic versions, which are generally available after the patent expires, contain the identical active ingredient and are required to be bioequivalent to the brand-name product.

Q: Is Dicloberl safe for long-term use?

Regulatory documents state that treatment should be administered at the lowest effective dose for the shortest duration possible. High doses and long-term use are associated with a documented increase in the risk of serious cardiovascular and gastrointestinal adverse events.

Q: What is the maximum duration people usually take Dicloberl for?

Official documentation strongly advises limiting the duration of use to the shortest time needed for symptomatic relief. For example, the injectable form has a strict limit of two consecutive days of use. For oral forms, the maximum duration is not universally fixed, and the duration of use should be re-evaluated periodically.

Q: Does Dicloberl have a risk of addiction?

Dicloberl is classified as a Non-steroidal anti-inflammatory drug (NSAID). NSAIDs are not controlled substances and official documents do not associate them with a risk of dependence or addiction.

Q: Can Dicloberl interact with herbal supplements?

Official public health guidance advises caution regarding the combination of diclofenac with herbal remedies and supplements. This is because these products are not typically tested for interactions in the same way as prescription medicines, and official public health guidance states that there is limited information to confirm their safety when taken together.

Q: Is there a generic version of Dicloberl?

Yes, the active ingredient diclofenac is widely available in various generic forms after the original brand-name patent expires. Generic drugs are approved to contain the same active ingredient and are required to be bioequivalent to the brand-name product.

Q: Is Dicloberl appropriate for people with kidney issues?

The medicine is contraindicated in patients with advanced renal disease. Patients who have pre-existing renal impairment should be treated with caution and monitored, as NSAIDs can cause a dose-dependent reduction in blood flow to the kidneys.

Q: Can children or teenagers use Dicloberl?

Systemic forms are generally not recommended for use in pediatric patients under 14 years of age. Use in children younger than 12 years is not established for many systemic forms. Suitability for use in teenagers is an individual decision to be made by a healthcare provider.

Q: What should I do if I miss a scheduled time to take Dicloberl?

Official patient guidance recommends taking the missed dose as soon as possible, unless it is almost time for the next scheduled dose. If it is almost time for the next dose, the missed dose is generally advised to be skipped to return to the regular schedule. Doses should not be doubled.

Q: Can I take Dicloberl if I have a history of heart problems?

Dicloberl is contraindicated (must not be used) in patients with established Ischaemic Heart Disease, certain classes of Congestive Heart Failure, Peripheral Arterial Disease, or Cerebrovascular Disease due to a documented risk of thrombotic events. Patients with significant risk factors for heart events are described in official documents as requiring careful assessment.

Q: Does Dicloberl affect liver function?

Adverse reactions affecting the liver (hepatobiliary disorders, including hepatitis and liver failure) are documented in the safety profile. Regulatory information notes that elevated liver enzymes have been reported as a common side effect.

Q: Does taking Dicloberl affect performance in sports or driving?

Official safety summaries contain a warning that driving or operating machinery should be avoided if adverse reactions such as dizziness or vertigo are experienced.

Q: Does Dicloberl interact with antidepressants or mood stabilizers?

Regulatory warnings mention an increased risk of gastrointestinal bleeding when diclofenac is used together with certain medicines, including Selective Serotonin Reuptake Inhibitors (SSRIs).

Q: Is Dicloberl known to cause sun sensitivity?

Increased sensitivity of the skin to sunlight (photosensitivity) is listed as a less common skin reaction in some official safety information. Patients are advised to be aware of the potential for this effect.

Q: Does Dicloberl come in different strengths?

Yes, official regulatory documents list different recommended dosages (e.g., 25 mg, 50 mg, 75 mg) for the various conditions it is used for. This indicates that the medicine is manufactured and available in various strengths.

Q: Does Dicloberl interact with other pain relievers like naproxen?

Co-administration with other systemic NSAIDs, such as naproxen, is generally restricted. This is due to an established, additive risk of serious gastrointestinal adverse events when multiple medicines in this pharmacological class are taken together.

Q: Do clinical trials mention a maximum number of days to take Dicloberl?

Official documentation consistently requires treatment to be for the shortest duration possible. While a universal maximum number of days for oral use is not fixed, the need for continued symptomatic relief should be re-evaluated periodically.

Q: Is it common to feel dizzy after taking Dicloberl?

Yes, dizziness is listed as a common adverse reaction in official safety documents. This means it has been reported to affect up to 1 in 10 people in clinical data and post-marketing surveillance.

How should Dicloberl be stored and disposed of?

Storage and Disposal of Dicloberl

The storage and disposal of Dicloberl (Diclofenac) must adhere strictly to the conditions documented in official regulatory labeling to ensure product stability and safety.

Storage Conditions

Requirement	Official Regulatory Instruction
Temperature	Store below 25 C or 30 C, depending on the specific formulation.
Protection	Keep the product in the original container/package to protect it from light and moisture.
Handling	Do not freeze the product.
Child Safety	The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Dicloberl must not be discarded into wastewater or household trash. Disposal must occur in accordance with local requirements, typically by returning the medicine to a pharmacy or designated collection point.

Dicloberl